Financial Solutions Advisory Group Inc. Boosts Stock Holdings in Abbott Laboratories $ABT

Financial Solutions Advisory Group Inc. grew its stake in shares of Abbott Laboratories (NYSE:ABT) by 136.7% during the second quarter, Holdings Channel reports. The institutional investor owned 23,590 shares of the healthcare product maker’s stock after purchasing an additional 13,623 shares during the quarter. Abbott Laboratories comprises 0.3% of Financial Solutions Advisory Group Inc.’s portfolio, making the stock its 27th biggest holding. Financial Solutions Advisory Group Inc.’s holdings in Abbott Laboratories were worth $2,227,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Southland Equity Partners LLC boosted its stake in shares of Abbott Laboratories by 3.2% during the second quarter. Southland Equity Partners LLC now owns 8,484 shares of the healthcare product maker’s stock valued at $770,000 after purchasing an additional 266 shares during the period. SteelPeak Wealth LLC boosted its position in Abbott Laboratories by 9.6% during the 2nd quarter. SteelPeak Wealth LLC now owns 3,529 shares of the healthcare product maker’s stock valued at $320,000 after buying an additional 308 shares during the period. Woodstock Corp increased its position in shares of Abbott Laboratories by 5.3% in the second quarter. Woodstock Corp now owns 144,252 shares of the healthcare product maker’s stock valued at $13,089,000 after acquiring an additional 7,215 shares during the period. DAVENPORT & Co LLC raised its stake in shares of Abbott Laboratories by 92.3% during the second quarter. DAVENPORT & Co LLC now owns 1,827,013 shares of the healthcare product maker’s stock valued at $166,732,000 after acquiring an additional 876,954 shares during the last quarter. Finally, Investors Research Corp boosted its holdings in shares of Abbott Laboratories by 7,781.2% during the second quarter. Investors Research Corp now owns 6,305 shares of the healthcare product maker’s stock worth $572,000 after purchasing an additional 6,225 shares during the period. 75.18% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on ABT shares. Piper Sandler restated an “overweight” rating and set a $118.00 price target (up from $115.00) on shares of Abbott Laboratories in a report on Friday, July 17th. BTIG Research boosted their target price on Abbott Laboratories from $131.00 to $134.00 and gave the company a “buy” rating in a research note on Friday, July 17th. Benchmark dropped their price target on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a research note on Friday, April 17th. Stifel Nicolaus reduced their price objective on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a research report on Friday, April 17th. Finally, Robert W. Baird assumed coverage on shares of Abbott Laboratories in a research note on Wednesday, July 1st. They set an “outperform” rating and a $121.00 target price on the stock. Three analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $118.17.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Bank of America issues a Buy rating: The endorsement from Bank of America Securities adds to positive Wall Street sentiment and may support investor confidence in Abbott’s earnings and growth outlook. Abbott Laboratories Receives a Buy from Bank of America Securities
• Positive Sentiment: Abbott and Google expand glucose-monitoring partnership: Abbott will integrate Lingo glucose data with Google’s AI-driven consumer health tools. The companies also plan a large real-world metabolic-health study, potentially improving personalized coaching, supporting future Lingo features and increasing the commercial value of Abbott’s biowearable platform. Abbott Laboratories Ties Lingo Glucose Data to AI Health Tools
• Positive Sentiment: Potential cardiovascular innovation: Abbott’s ongoing PULSE study is evaluating early treatment for atrial fibrillation. Positive results could strengthen Abbott’s electrophysiology portfolio, although the study remains a longer-term catalyst and does not yet establish a commercial benefit. Early AF Treatment on Trial: What Abbott’s PULSE Study Could Mean for Investors
• Neutral Sentiment: Blood-donation campaign returns: Abbott and the Big Ten revived the “We Give Blood” campaign amid a U.S. blood shortage. The initiative enhances Abbott’s public profile and reinforces its healthcare mission, but it is unlikely to have a material near-term effect on earnings. Abbott and Big Ten Bring Back We Give Blood

Abbott Laboratories Price Performance

Shares of ABT opened at $110.92 on Thursday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. The firm’s 50-day simple moving average is $96.86 and its two-hundred day simple moving average is $99.73. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $137.49. The stock has a market cap of $191.93 billion, a PE ratio of 35.90, a price-to-earnings-growth ratio of 2.12 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. The company had revenue of $12.59 billion during the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The firm’s revenue for the quarter was up 13.0% on a year-over-year basis. During the same quarter last year, the company earned $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Analysts anticipate that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be paid a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. The ex-dividend date is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio is currently 81.55%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.